Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women

Breast Cancer Research and Treatment

Volumn 138, Issue 2, 2013, Pages 611-619

  Lajin, Bassam ^a   Alhaj Sakur, Amir ^a   Alachkar, Amal ^b  

^a UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Breast cancer; NQO1; p53; Polymorphism

Indexed keywords

PROTEIN P53;

ADULT; AGED; APOPTOTIC GENE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; NQO1 GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYRIAN; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STABILITY; SEQUENCE ANALYSIS, DNA; SYRIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879412565     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2467-4     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010
2. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879-1886 (Pubitemid 20026073)
3. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Gene 1(1):45-49
4. Roy B, Beamon J, Balint E, Reisman D (1994) Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14(12):7805-7815 (Pubitemid 24373530)
5. Pavletich NP, Chambers KA, Pabo CO (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7(12B):2556-2564 (Pubitemid 24021012)
6. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39(Database issue):D945-D950
7. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98(3):1188-1193 (Pubitemid 32121208)
8. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM (2003) Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol Endocrinol 17(7):1344-1355 (Pubitemid 36819955)
9. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S et al (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10(4):307-311
10. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6(2):105-112 (Pubitemid 27069203)
11. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10(3):711-714
12. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92(6):1144-1148 (Pubitemid 40546682)
13. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30(6):523-529 (Pubitemid 44828290)
14. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90(10):1989-1994 (Pubitemid 38746342)
15. Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA et al (2005) Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet 116(3):208-221 (Pubitemid 40174007)
16. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE (2007) Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 16(9):1784-1794 (Pubitemid 47450508)
17. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P (2004) Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 12(10):848-854 (Pubitemid 39406070)
18. Siegelmann-Danieli N, Buetow KH (2002) Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 62(1):39-45 (Pubitemid 34124224)
19. Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M (2011) P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 28(3):709-715
20. Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2010) Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16 bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 34(2):184-188
21. Lajin B, Alachkar A, Alhaj Sakur A (2012) A quadruplex tetra-primer ARMS-PCR method for the simultaneous detection of TP53 Arg72Pro, IVS3 16 bp Del/Ins and IVS6+62A>G, and NQO1 C609T polymorphisms. Gene 504(2):268-273
22. Slatkin M, Excoffier L (1996) Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 76(Pt 4):377-383
23. Yoo J, Lee Y, Kim Y, Rha SY, Kim Y (2008) SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. BMC Bioinform 9:290 (Pubitemid 351984849)
24. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357-365 (Pubitemid 36278852)
25. Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG Jr, Crook T (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60(24):6875-6877 (Pubitemid 32059156)
26. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B et al (2004) Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 164(4):1233-1241 (Pubitemid 38387790)
27. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K (2000) p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 60(11):2753-2755 (Pubitemid 30395785)
28. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6(5):529-535 (Pubitemid 39411089)
29. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25(1):47-54 (Pubitemid 30257035)
30. van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Helmerhorst TJ, Meijer CJ, Walboomers JM (2000) Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81(Pt 2):317-325 (Pubitemid 30077274)
31. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V (1999) Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 6(1):193-197
32. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393(6682):229-234 (Pubitemid 28261713)
33. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L (2010) Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 31(4):643-647
34. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23(10):1954-1956 (Pubitemid 38445422)
35. He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, Wang W, Arparkorn K (2011) Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 130(2):517-529
36. Nikbakht Dastjerdi M, Mirmohammad SH (2010) TP53 codon 72 heterozygosity may promote microsatellite instability in sporadic colorectal cancer. YAKHTEH 12:1-6
37. Toyama T, Iwase H, Yamashita H, Iwata H, Yamashita T, Ito K, Hara Y, Suchi M, Kato T, Nakamura T et al (1996) Microsatellite instability in sporadic human breast cancers. Int J Cancer 68(4):447-451 (Pubitemid 26414498)
38. Anbazhagan R, Fujii H, Gabrielson E (1999) Microsatellite instability is uncommon in breast cancer. Clin Cancer Res 5(4):839-844 (Pubitemid 29180836)
39. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE (2008) High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 99(3):404-407
40. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE (2000) Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 88(9):2082-2091 (Pubitemid 30233210)
41. Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, Caceres E, Peixoto-Guimaraes D, Lenoir G, Hainaut P et al (2001) TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 10(9):1009-1012 (Pubitemid 32844911)
42. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 59(2):263-268 (Pubitemid 32108559)
43. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237-1245
44. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591-602 (Pubitemid 39535748)
45. Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011) Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 15(5):343-349
46. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y et al (2002) NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7(2):103-108 (Pubitemid 34538454)
47. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W (2004) Oral contraceptive use and breast cancer risk: modification by NAD(P)H: quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 13(8):1308-1315 (Pubitemid 39071554)
48. Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, Li D (2011) Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 125(2):467-472
49. Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A (2012) The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett 3(4):875-878
50. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44(5):266-270 (Pubitemid 24229554)
51. Al-Qasem AJ, Toulimat M, Eldali AM, Tulbah A, Al-Yousef N, Al-Daihan SK, Al-Tassan N, Al-Tweigeri T, Aboussekhra A (2011) TP53 genetic alterations in Arab breast cancer patients: novel mutations, pattern and distribution. Oncol Lett 2(2):363-369
52. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94(9):681-690 (Pubitemid 34552489)